PDCD1 and melanoma: The first FDA-approved therapy was a CTLA-4 inhibitor, ipilimumab, for melanoma,379–381 followed by the PD-1 inhibitor nivolumab, which displayed significant effects with tolerable adverse events in a phase I trial and went through subsequent phase II and III trials.